TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Botulinum Neurotoxin Type A

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

NINDS encourages small business research grant applications to develop in-vitro assays to assess the potency of Botulinum Neurotoxin Type A. This announcement is made together with the Food and Drug Administration and is supported by 2 funding mechanisms: R41/R42 and R43/R44.

Therapeutic uses of botulinum toxin have increased steadily since its initial approval. Presently, type A neurotoxin is in widespread clinical use and its potency is assessed in a mouse model with inherent variability. The purpose of this announcement is to encourage development of new non-animal-based assays to assess the potency of botulinum neurotoxin type A.

Potential applicants should contact Dr. Danilo Tagle, program director, Neurogenetics Cluster, NINDS; telephone: 301-496-5745; email: tagled@ninds.nih.gov. For more information visit http://grants.nih.gov/grants/guide/pa-files/PA-09-178.html and http://grants.nih.gov/grants/guide/pa-files/PA-09-179.html.